Preeclampsia is a pregnancy complication characterized by the onset of high blood pressure that occurs after 20 weeks of pregnancy. Pregnant women are prone to infection by COVID-19 and the risk of pregnancy complications. These causes can effect complications in maternal outcomes such as HELLP syndrome, pulmonary edema, acute kidney failure, and eclampsia, which will affect methods of childbirth and even cause maternal death. The purpose of this study is to determine the differences in maternal outcomes of preeclampsia with COVID-19 and without COVID-19.This study is an analytical observational with a retrospective approach using chi-square test and fisher exact test as an alternative, using secondary data from medical records of preeclampsia patients with COVID-19 and without COVID-19 at RSUD Ulin Banjarmasin for May 2020 – April 2021. The results showed there were differences in outcomes of methods of childbirth (p=0,001) while there were no differences in outcomes of HELLP syndrome (p=0,554), eclampsia (p=0,960), kidney failure (p=0,139), pulmonary edema (p=0,730), and maternal death (p=0,521). From those results, it can be concluded that there were differences in outcomes of methods of childbirth and there were no differences in outcomes of HELLP syndrome, eclampsia, kidney failure, pulmonary edema, and maternal death in preeclampsia patients with COVID-19 and without COVID-19. Keywords: maternal outcomes, preeclamsia, COVID-19 Abstrak: Preeklampsia adalah gangguan kehamilan ditandai hipertensi setelah 20 minggu kehamilan. Ibu hamil rentan terjangkit COVID-19 dan berisiko komplikasi kehamilan. Gangguan ini mengakibatkan terjadinya luaran maternal seperti sindrom HELLP, edema paru, gagal ginjal akut, eklampsia, mempengaruhi metode persalinan bahkan kematian ibu. Tujuan penelitian ini untuk mengetahui perbedaan luaran maternal pasien preeklampsia dengan COVID-19 dan tanpa COVID-19. Penelitian ini bersifat observasional analitik dengan pendekatan retrospektif menggunakan uji chi-square dan uji fisher exact sebagai alternatif, menggunakan data sekunder dari rekam medik pasien preeklampsia dengan COVID-19 dan tanpa COVID-19 di RSUD Ulin Banjarmasin periode Mei 2020 – April 2021. Hasil penelitian menunjukkan perbedaan luaran metode melahirkan (p=0,001), sedangkan luaran sindrom HELLP (p=0,554), eklampsia (p=0,960), gagal ginjal (p=0,139), edema paru (p=0,730), dan kematian (p=0,521) tidak terdapat perbedaan. Kesimpulan penelitian terdapat perbedaan luaran metode melahirkan dan tidak terdapat perbedaan luaran sindrom HELLP, eklampsia, gagal ginjal, edema paru dan kematian pada pasien preeklampsia dengan COVID-19 dan tanpa COVID-19. Kata-kata kunci: luaran maternal, preeklampsia, COVID-19
Preeclampsia is a serious complication of pregnancy and occurs in 3-8% of all pregnancies. Preeclampsia can affect newborn, causing hypoxia, Intra Uterine Growth Retardation, preterm labor and low birth weight babies (LBW). Pregnant women are easily infected by SARS-CoV-2. Fetal complications of mothers that infected with COVID-19 include miscarried, IUGR, and preterm birth. Preeclampsia can be exacerbated or exacerbate by COVID-19 which has an impact of the condition of the newborn. The purpose of this study was to determine difference of neonatal outcomes of preeclampsia mothers with COVID-19 and without COVID-19 at Ulin Hospital Banjarmasin for the period May 2020-April 2021. This study was an analytical observational study with a retrospective approach used the Chi-square test and Fisher's exact test as an alternative. The data used was from medical records. The sample used was neonates born to preeclampsia mothers with COVID-19 and without COVID-19 at Ulin Hospital Banjarmasin for the period May 2020-April 2021, selected by purposive sampling and met the inclusion and exclusion criteria. The results showed a significant difference of the outcome of the length of stay of neonates (p= 0.002) and no significant difference of the outcomes of neonates with low birth weight (p= 0.271), preterm (p= 0.126), the 1st minute (p= 0.731) and 5th minute (p= 0.993) of APGAR score, and mortality (p= 0.240). The conclusion of this study is there was only a difference in the length of stay while the other outcomes did not. Keywords: neonatal outcome, preeclampsia, COVID-19 Abstrak: Preeklamsia merupakan komplikasi kehamilan berat dan terjadi sekitar 3-8% dari keseluruhan kehamilan. Preeklampsia dapat berpengaruh terhadap bayi yang dilahirkan, menyebabkan hipoksia, pertumbuhan janin terhambat, persalinan prematur dan bayi berat lahir rendah (BBLR). Ibu hamil mudah terinfeksi oleh SARS-CoV-2. Komplikasi janin pada ibu yang terinfeksi COVID-19 berupa keguguran, IUGR, dan kelahiran prematur. Preeklampsia dapat diperburuk atau memperburuk kehamilan dengan COVID-19 yang berdampak pada kondisi bayi yang dilahirkan. Tujuan penelitian untuk mengetahui perbedaan luaran neonatal pada ibu preeklampsia dengan COVID-19 dan tanpa COVID-19 di RSUD Ulin Banjarmasin periode Mei 2020-April 2021. Penelitian berupa observasional analitik dengan pendekatan retrospektif menggunakan uji Chi-square dan Fisher’s exact test sebagai alternatif. Data yang digunakan dari rekam medik. Sampel penelitian berupa neonatus yang lahir dari ibu preeklampsia dengan COVID-19 dan tanpa COVID-19 di RSUD Ulin Banjarmasin periode Mei 2020-April 2021, dipilih secara purposive sampling dan memenuhi kriteria inklusi dan eksklusi. Hasil penelitian terdapat perbedaan bermakna (p= 0,002) pada luaran lama rawat inap neonatus dan tidak terdapat perbedaan bermakna pada luaran neonatus dengan BBLR (p= 0,271), prematur (p= 0,126), skor APGAR neonatus menit ke-1 (p= 0,731) dan ke-5 (p= 0,993), dan meninggal (p= 0,240). Kesimpulan penelitian hanya terdapat perbedaan pada luaran lama rawat inap sedangkan luaran lainnya tidak. Kata-kata kunci: luaran neonatal, preeklampsia, COVID-19
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.